Who owns Obsidian Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of OBX from SEC Form 13F filings across 60 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 60 institutions disclosed 50.6M shares of Obsidian Therapeutics, Inc. worth $695.4M — about 123.4% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
60
13F holders
$695.4M
value, 2026 filers
123.4%
of shares outstanding (50.6M sh)
60
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of OBX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P.NEW | 6.0M | $81.8M | 0.8% | 14.5% | new |
| 2 | Atlas Venture Life Science Advisors, LLCNEW | 4.5M | $61.8M | 9.8% | 11% | new |
| 3 | Paradigm Biocapital Advisors LPNEW | 4.2M | $57.1M | 1.1% | 10.1% | new |
| 4 | NOVO HOLDINGS A/SNEW | 3.1M | $42.9M | 2.9% | 7.6% | new |
| 5 | Trails Edge Capital Partners, LPNEW | 2.5M | $34.3M | 4.9% | 6.1% | new |
| 6 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 2.4M | $33.5M | 0.0% | 6% | new |
| 7 | Octagon Capital Advisors LPNEW | 2.4M | $33.2M | 4.4% | 5.9% | new |
| 8 | TCG Crossover Management, LLCNEW | 2.2M | $30.2M | 0.9% | 5.4% | new |
| 9 | Deep Track Capital, LPNEW | 2.1M | $29.1M | 0.5% | 5.2% | new |
| 10 | CITADEL ADVISORS LLCNEW | 1.9M | $26.7M | 0.0% | 4.7% | new |
| 11 | Blue Owl Capital Holdings LPNEW | 1.5M | $20.4M | 3.7% | 3.6% | new |
| 12 | Spruce Street Capital LPNEW | 1.2M | $17.2M | 2.7% | 3% | new |
| 13 | Alphabet Inc.NEW | 1.2M | $16.8M | 0.0% | 3% | new |
| 14 | Nantahala Capital Management, LLCNEW | 1.2M | $16.5M | 0.5% | 2.9% | new |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/NEW | 1.1M | $14.5M | 0.0% | 2.6% | new |
| 16 | Nan Fung Group Holdings LtdNEW | 918,765 | $12.6M | 8.4% | 2.2% | new |
| 17 | Foresite Capital Management VI LLCNEW | 916,063 | $12.6M | 2.2% | 2.2% | new |
| 18 | Caligan Partners LPNEW | 886,281 | $12.2M | 0.7% | 2.2% | new |
| 19 | Pivotal bioVenture Partners Investment Advisor LLCNEW | 860,343 | $11.8M | 4.7% | 2.1% | new |
| 20 | SAMSARA BIOCAPITAL, LLCNEW | 837,173 | $11.5M | 1.1% | 2% | new |
| 21 | Redmile Group, LLCNEW | 833,157 | $11.4M | 0.8% | 2% | new |
| 22 | BlackRock, Inc.NEW | 775,759 | $10.7M | 0.0% | 1.9% | new |
| 23 | Janus Henderson Group Ltd.NEW | 728,700 | $10.0M | 0.0% | 1.8% | new |
| 24 | EVENTIDE ASSET MANAGEMENT, LLCNEW | 624,972 | $9.1M | 0.1% | 1.5% | new |
| 25 | Balyasny Asset Management L.P.NEW | 587,724 | $7.8M | 0.0% | 1.4% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.